報價延遲最少15分鐘:2025/09/05 18:01 EDT
盤後時段
|
||||
|
2.77 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.59/-2.01
|
|
企業價值
250.01M
|
| 資產負債 |
|
每股賬面淨值
2.45
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
21.38M
|
|
每股收益
0.29
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/05 18:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harnessthe body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919. |
